AccelStor Partners with Tiger Technology for Top-Notch Media Production Solutions
AccelStor, the software-defined all-flash array provider, is proud to announce that its NeoSapphire 3605 and NeoSapphire 3611 Fibre Channel all-flash arrays have been officially certified by Tiger Technology, listing AccelStor as a partner for Fibre Channel storage and connectivity. This pairing creates an ideal solution for collaborating video production teams who need to access the same data, fast.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161116005028/en/
AccelStor and Tiger Solution (Graphic: Business Wire)
Thanks to AccelStor’s partnership with Tiger Technology, video professionals now have an ideal solution to drastically improve their workflows. The NeoSapphire all-flash array is designed to remove the performance bottleneck inherent in the intensive workloads of collaborative editing. The Tiger Series shared storage management solution is designed for video editing and post workgroups. It helps media professionals achieve a true SAN workflow by providing multiple Windows, Mac OS X, and Linux workstations concurrent, managed access to shared data. This allows multiple simultaneous users to access a single storage node, and streamline their production workflow with user and team management, while AccelStor’s flash arrays dramatically increase total throughput. In tandem, this solution removes the bottleneck found in NAS systems, easing access of enormous video files.
With the advent of ultra high definition imaging, video editors have many challenges in their production workflows: 4K video editing requires high throughput and low latency storage in order to handle real-time editing, color grading, special effects, and mastering for every second of footage. Raw materials also need to be shared across departments and accessed by many different users. AccelStor’s NeoSapphire 3605 and NeoSapphire 3611 Fibre Channel All-Flash Arrays handle the extreme I/O workload and provide metadata storage to quickly dispatch data to the desired volume via the Storage Area Network. Traditional HD storage is too slow and creates a bottleneck for production teams needing to access video from multiple workstations.
“At AccelStor, we always strive to achieve the best user experience for professionals. We are proud to partner with industry leaders like Tiger Technology,” said Alan Lin, Senior Manager of AccelStor, “We aim to demonstrate our commitment to media production professionals who consistently cope with some of the most challenging storage demands in their work.”
“AccelStor all-flash arrays provide the extreme performance needed for 2K, 4K, UHD, and even 8K content production. The combination of AccelStor all flash arrays and Tiger’s advanced yet simple storage and workflow management creates an ideal solution for the demands of high-resolution media production,” added Angus Mackay, Tiger Technology Marketing Director.
AccelStor’s NeoSapphire 3605 and NeoSapphire 3611 all-flash arrays have been made compatible with Tiger’s collaborative workflow software. The high throughput and low latency of these arrays create amazing results together with Tiger software suites. Dual-port 16G Fibre Channel, and backward compatibility with 8G, and Tiger Technology Smart Pooling makes these arrays easy to integrate into existing SANs without the need to copy or migrate data. Their Multipathing feature allows connection redundancy for I/O balance, fail-over, and seamless fault recovery. These storage solutions are all but necessitated by the increasing demands and ubiquity of UHD videos.
AccelStor is accelerating the paradigm shift from conventional disk arrays to modern all-flash storage. AccelStor's NeoSapphire series all-flash arrays, powered by FlexiRemap software technology, deliver sustained high IOPS to business-critical applications. With standard rack-mount form factors, streamlined storage management, multi-protocol support, as well as front-accessible and hot-swappable drives, NeoSapphire promises to resolve the performance bottlenecks for I/O-intensive applications like virtualization, high-performance computing, database, and media-processing applications. For more information about AccelStor and NeoSapphire, please visit www.accelstor.com.
* AccelStor, FlexiRemap, and NeoSapphire are trademarks or registered trademarks of AccelStor, Inc. in the United States of America and/or other countries. Other names and brands may be claimed as the property of others.
About Tiger Technology
Tiger Technology is a developer of advanced shared storage workflow solutions including software management tools and integrated appliances. The company’s cross-platform file sharing management solutions set new standards for multiple users sharing and managing access to bandwidth intensive data consolidated on a centralized storage location. For further information on Tiger Technology please visit www.tiger-technology.com.
Clara Lee, +886-2-77467616 ext. 2561
Angus Mackay, +1-514-758-0922
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Philip Morris International Releases Latest Scientific Update for Smoke-Free Products on Clinical Program12.12.2017 15:23 | Pressemelding
Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) today released its latest Scientific Update for Smoke-Free Products, a regular publication on its research efforts to develop and assess a range of smoke-free alternatives to cigarettes. The latest issue of the Scientific Update can be found at this link. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171212005891/en/ Philip Morris International Releases Latest Scientific Update for Smoke-Free Products on Clinical Program (Photo: Business Wire) This issue of the Scientific Update provides a closer look at some of the principles and practices on which PMI’s scientific assessment program is built. Director Medical Affairs Dr. Patrick Picavet describes specific examples from PMI’s clinical program that highlight the company’s
Murex to Offer MX.3 Risk, Trading and Post-Trade Solutions on the AWS Cloud12.12.2017 14:00 | Pressemelding
Murex, an industry leader in trading, risk management and processing solutions for capital markets, announced they will run their MX.3 technology platform on Amazon Web Services, Inc. (AWS). With the acceleration of cloud adoption in capital markets, Murex and AWS agreed to collaborate to help clients migrate their Murex application workloads to the AWS Cloud. Murex clients are looking to consolidate more and more of their capital markets activity on the MX.3 platform and this means their need for infrastructure is increasing. New regulatory requirements are also driving financial organizations to use cloud to scale up their computing capacity. Murex is collaborating with AWS to meet the demand from clients to support deployment of the Murex offering on the AWS Cloud. Murex is working on the validation of a range of deployment scenarios, from using AWS Cloud for bursting grid
Darzalex®▼(daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible12.12.2017 13:33 | Pressemelding
Janssen-Cilag International NV (“Janssen”) today announced data from the Phase 3 ALCYONE study, showing Darzalex® (daratumumab) in combination with bortezomib, melphalan and prednisone (VMP) significantly improved clinical outcomes, including reducing the risk of disease progression or death by 50 percent, in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (ASCT).1 These data were accepted as a late-breaking abstract (LBA) for presentation at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, today at 7:30 a.m. ET (Abstract #LBA-4).1 Study findings were simultaneously published in the New England Journal of Medicine (NEJM) . 2 Daratumumab is currently indicated for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for
CTS Engines Announces Senior Management Hire12.12.2017 13:00 | Pressemelding
CTS Engines, the global leader for mature jet engine maintenance, announced today that it had hired Diane E. Cavuoto as Senior Vice President, Supply Chain, in an effort to continue to provide its customers with outstanding engine overhaul services. Ms. Cavuoto will be based in CTS’s Ft. Lauderdale headquarters and will report directly to Vesa Paukkeri, CTS’s President and Chief Operating Officer. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171212005050/en/ Diane E. Cavuoto, Senior Vice President, Supply Chain, for CTS Engines (Photo: Business Wire) Ms. Cavuoto, most recently Vice President, Strategic Sourcing at Honeywell International, brings years of supply chain management experience to CTS. In her prior role at Honeywell, Ms. Cavuoto managed a global commodity team of 150 employees managing $4
MIPI Alliance Opens Access to its MIPI I3C Sensor Interface Specification12.12.2017 13:00 | Pressemelding
The MIPI® Alliance, an international organization that develops interface specifications for mobile and mobile-influenced industries, today announced it is opening access to its sensor interface specification, MIPI I3C. Starting today, all companies, including those not currently members of MIPI Alliance, may access the MIPI I3C v1.0 specification so they may evaluate the incorporation of the specification into their sensor integration plans and design applications. “MIPI I3C provides a welcome update to the I2C technology that has been widely adopted over the past 35 years. Extending access provides an opportunity to spur innovation and help other industries beyond mobile," said Joel Huloux, chairman of MIPI Alliance. "It helps MIPI members as well, because it supports greater adoption and interoperability, strengthens the ecosystem and provides for a richer
ADC Therapeutics Announces Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-30112.12.2017 11:23 | Pressemelding
ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-301 (camidanlumab tesirine or “Cami-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-301 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Hodgkin’s or non-Hodgkin’s lymphoma Dr. Steven M. Horwitz, Medical Oncologist at Memorial Sloan Kettering Cancer Center in New York City, and Principal Investigator, s
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom